Month: June 2023

Mobilicom’s MCU-70 expands communications range to 100 miles with improved link performance, more power, better resilience & durability Significantly expands Mobilicom’s addressable market to mid-sized, long-range drones, a $6.8 B market, providing its Tier 1 customers a one-stop-shop for end-to-end solutions in military and commercial applications Equipped for ICE Cybersecurity software to provide essential protection against increasing cyberattacks as evidenced in the Ukraine conflict where 10,000 drones a month are lost to Russian electronic-warfare systemsShoham, Israel, June 29, 2023 (GLOBE NEWSWIRE) —  Mobilicom Limited (Mobilicom or the Company, NASDAQ: MOB, MOBBW ; ASX: MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced the launch of its latest product, the MCU-70,...

TORONTO, June 29, 2023 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE:NVRO | OTCQB:ESGLF | FSE:YGK) (“EnviroGold Global” or the “Company”), a clean technology company accelerating the world’s transition to a circular-resource economy, is pleased to announce the successful completion of its pilot plant test work campaign for the Hellyer Project (“Hellyer”). The Hellyer project is a joint project between EnviroGold Global and Hellyer Metals that includes an off-site pilot study at the world-renowned ALS Laboratory in Perth Australia. The test results confirmed excellent liberation of critical and precious metals using EnviroGold Global’s proprietary hydrometallurgical process and support the designed process flowsheet. The Company is pleased to report that the pilot plant testing, undertaken at the world-renowned ALS Laboratory...

Appointment Strengthens PWP’s Industrials Practice Underscores Firm’s Commitment to Scaling Business NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) — Perella Weinberg Partners (Nasdaq: PWP), a leading global independent advisory firm, announced today that Christopher Doolin has joined the Firm as a Partner in the Advisory Business. Based in Chicago, Mr. Doolin will work in the Firm’s Industrials Group and provide strategic and financial advice to clients globally across the Business and Consumer Services sectors. Mr. Doolin joins PWP with over 15 years of investment banking experience, advising corporate and financial sponsor clients on strategy and transformative M&A as well as equity and debt capital raising. “We are thrilled to have Chris join our team and expand client coverage in this critical and active sector,” said Andrew...

Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS) SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) — (June 29, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the achievement of a development milestone which triggers a $5 million payment from its research and development collaboration with Merck (known as MSD outside the United States and Canada). This collaboration, focused on the discovery and development of novel candidates for the treatment of amyotrophic lateral sclerosis (ALS), originated from an agreement between Yumanity Therapeutics and Merck. “We are proud to achieve this milestone in our collaboration with Merck,” said Shawn...

Parsons to Serve as Lead Designer CENTREVILLE, Va., June 29, 2023 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) today announced that the company will serve as lead designer to the Skanska Halmar JFK Joint Venture in support of a $1.24 billion design and reconstruction of John F. Kennedy International Airport’s Central Terminal Area Roadways, Utilities and Ground Transportation Center (GTC) in Queens, New York. Skanska, a leading global construction and development firm, and joint venture partner, Halmar International, LLC, was awarded a contract by the Port Authority of New York and New Jersey to carry out the project, which will improve the airport’s roadway network by creating an easier to navigate and more user-friendly airport experience. “We are honored to have the opportunity to design and construct a world-class landside...

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 29 JUNE 2023 AT 13.30 P.M. EET, OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGEOma Savings Bank Plc updates its medium-term financial goals regarding comparable return on equity and capital adequacy At its meeting on 29 June 2023, the Board of Directors of Oma Savings Bank Plc (OmaSp or the Company) has updated its medium-term (3-5 years) financial goals as part of its strategy process and updates its medium-term return on equity and capital adequacy. The Company’s updated target level for comparable return on equity (ROE) is at least 16 percent instead of the previous 10 percent. The updated target level for the Common Equity Tier 1 (CET1) capital ratio is at least 2 percentage points above the regulatory requirement instead of the previous target of at least 14 percent....

Fashion-forward retailer extends its strong relationship with Macerich on Long IslandPrimark at Green Acres Mall Primark Opening at Green Acres Mall, A Macerich PropertySANTA MONICA, Calif., June 29, 2023 (GLOBE NEWSWIRE) — Macerich (NYSE: MAC), one of the nation’s leading owners, operators and developers of one-of-a-kind retail and mixed-use properties in top markets, today announced that Primark has opened a new Long Island store at Green Acres Mall. Irish retail brand Primark is a leading international clothing retailer that draws shoppers to the high street worldwide with its wide selection of essentials and fashion favorites built around everyday affordability. At Green Acres, Primark is located in Center Court, adjacent to another prominent international retailer scheduled to open in Fall 2023. The two retailers replace...

The Extraordinary General Meeting of Shareholders of AB “Ignitis grupė” (hereinafter – the Group), legal entity code: 301844044, registered office address: Laisvės Ave. 10, Vilnius, which was held on 29 June 2023, adopted the following resolutions: 1. Regarding agreement to the reduction of the share capital of AB “Ignitis gamyba”, a subsidiary of AB “Ignitis grupė”.1.1. To agree to the reduction of the share capital of AB “Ignitis gamyba” from EUR 187,920,762.41 (one hundred and eighty-seven million nine hundred and twenty thousand seven hundred and sixty-two euros and forty-one cents) to EUR 90,000,000.12 (ninety million euros and twelve cents) by cancelling 337,657,801 ordinary registered uncertificated shares of AB “Ignitis gamyba” with a nominal value of EUR 0.29 each. The total value of the shares to be cancelled is EUR 97,920,762.29...

The Extraordinary General Meeting of Shareholders of AB “Ignitis grupė” (hereinafter – the Group), legal entity code: 301844044, registered office address: Laisvės Ave. 10, Vilnius, which was held on 29 June 2023, adopted the following resolutions: 1. Regarding agreement to the reduction of the share capital of AB “Ignitis gamyba”, a subsidiary of AB “Ignitis grupė”.1.1. To agree to the reduction of the share capital of AB “Ignitis gamyba” from EUR 187,920,762.41 (one hundred and eighty-seven million nine hundred and twenty thousand seven hundred and sixty-two euros and forty-one cents) to EUR 90,000,000.12 (ninety million euros and twelve cents) by cancelling 337,657,801 ordinary registered uncertificated shares of AB “Ignitis gamyba” with a nominal value of EUR 0.29 each. The total value of the shares to be cancelled is EUR 97,920,762.29...

 Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications The randomized Phase 3 trial is expected to enroll approximately 600 patients with metastatic, immunotherapy-resistant NSCLC at clinical trial sites initially in the United States, followed by Europe and other countries and regions The trial initiation follows the FDA Fast Track Designation granted in 2022, based on Phase 1/2 safety and efficacy data for the monotherapy in metastatic, immunotherapy-resistant NSCLC BNT316/ONC-392 is entering the pivotal clinical evaluation as part of BioNTech’s strategy to initiate multiple trials with registrational potential in 2023 and 2024MAINZ, Germany,...